candesartan has been researched along with Myocardial Infarction in 61 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving post-myocardial infarction cardiac remodeling." | 9.69 | Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients. ( Altunkeser, BB; Ates, MS; Aydoğan, C; Aygül, N; Demir, K; Polat, OC; Tezcan, H; Toprak, AM; Tunçez, A; Yalcin, MU, 2023) |
| "Ordinal analysis of vascular events showed no overall effect of candesartan in the subacute phase of stroke." | 9.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "Treatment with candesartan in the acute phase of stroke was not associated with clear long-term clinical benefits." | 9.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "The angiotensin receptor blocker candesartan appears to prevent diabetes in heart failure patients, suggesting that the renin-angiotensin axis is implicated in glucose regulation." | 9.11 | Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. ( Gerstein, HC; Granger, CB; McMurray, JV; Olofsson, B; Ostergren, JB; Pfeffer, MA; Probstfield, J; Swedberg, K; Yusuf, S, 2005) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 8.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "In patients with heart failure, candesartan significantly reduces the risk of the composite outcome of cardiovascular death or nonfatal MI." | 7.73 | Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. ( Demers, C; Granger, CB; Johansson, PA; McKelvie, RS; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Wang, D; Yusuf, S, 2005) |
| "The purpose of this study was to compare the angiotensin II type 1 receptor antagonist candesartan cilexitil (candesartan) and the angiotensin-converting enzyme inhibitor cilazapril on cardiac function, assessed by Doppler echocardiography and cardiac gene expression associated with cardiac remodeling, in rats with myocardial infarction." | 7.70 | Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. ( Akioka, K; Iwao, H; Kim, S; Omura, T; Takeuchi, K; Teragaki, M; Toda, I; Yamagishi, H; Yoshikawa, J; Yoshiyama, M, 1999) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 6.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| "Our results suggest that candesartan treatment following myocardial infarction may potentially be useful in terms of improving post-myocardial infarction cardiac remodeling." | 5.69 | Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients. ( Altunkeser, BB; Ates, MS; Aydoğan, C; Aygül, N; Demir, K; Polat, OC; Tezcan, H; Toprak, AM; Tunçez, A; Yalcin, MU, 2023) |
| "The authors pooled data from 3 trials-CHARM Preserved (Candesartan Cilexietil in Heart Failure Assessment of Reduction in Mortality and Morbidity), I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Function), and the Americas region of TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) (N = 8,916)-and examined whether MI before or following enrollment independently predicted CV death and heart failure (HF) hospitalization." | 5.34 | Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. ( Anand, IS; Carson, P; Claggett, BL; Cunningham, JW; Desai, AS; Jhund, PS; John, JE; Kober, L; Lewis, EF; McMurray, JJV; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Yusuf, S; Zile, MR, 2020) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 5.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| "Ordinal analysis of vascular events showed no overall effect of candesartan in the subacute phase of stroke." | 5.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "Treatment with candesartan in the acute phase of stroke was not associated with clear long-term clinical benefits." | 5.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "The angiotensin receptor blocker candesartan appears to prevent diabetes in heart failure patients, suggesting that the renin-angiotensin axis is implicated in glucose regulation." | 5.11 | Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. ( Gerstein, HC; Granger, CB; McMurray, JV; Olofsson, B; Ostergren, JB; Pfeffer, MA; Probstfield, J; Swedberg, K; Yusuf, S, 2005) |
| "We investigated the effects of the aldosterone blocker eplerenone alone and in combination with angiotensin II type 1 receptor antagonist on ventricular remodeling in rats with left ventricular (LV) dysfunction after extensive myocardial infarction (MI)." | 4.82 | Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. ( Omura, T; Yoshikawa, J; Yoshiyama, M, 2004) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| " In the nude rat chronic myocardial infarction model, we injected MSCs pretreated with candesartan (A-BM; n = 18) or injected MSCs without pretreatment of candesartan (BM; n = 25), each having survived for 2 weeks." | 3.77 | Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. ( Hida, N; Kimura, T; Miyoshi, S; Nishiyama, N; Numasawa, Y; Ogawa, S; Segawa, K; Tsuji, H; Tsuruta, H; Umezawa, A, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| "1 to 10 years) with reperfused ST-segment-elevation myocardial infarction (90 minutes of ischemia, 2 hours of reperfusion) to therapy with placebo or candesartan (1 mg/kg CV-11974) over 30 minutes from the onset of reperfusion." | 3.76 | Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. ( Idikio, H; Jelani, A; Jugdutt, BI; Jugdutt, CE; Menon, V; Palaniyappan, A; Uweira, RE, 2010) |
| "To determine whether therapy with the angiotensin II type 1 receptor blocker (ARB) candesartan and the comparator angiotensin-converting-enzyme inhibitor (ACEI) enalapril during healing after reperfused ST-elevation myocardial infarction (RSTEMI) limit adverse remodeling of infarct zone (IZ) collagens and left ventricular (LV) diastolic dysfunction, we randomized 24 dogs surviving anterior RSTEMI (90-min coronary occlusion) to placebo, candesartan, and enalapril therapy between day 2 and 42." | 3.74 | Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. ( Idikio, H; Jugdutt, BI; Uwiera, RR, 2007) |
| "In patients with heart failure, candesartan significantly reduces the risk of the composite outcome of cardiovascular death or nonfatal MI." | 3.73 | Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. ( Demers, C; Granger, CB; Johansson, PA; McKelvie, RS; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Wang, D; Yusuf, S, 2005) |
| "To determine whether angiotensin receptor blockade decreases vascular tone in heart failure by improving endothelial-dependent vasorelaxation and increasing nitric oxide (NO) bioavailability, we treated infarcted adult male Sprague-Dawley rats with candesartan for 7 days or 8 weeks (10 mg/kg/day in drinking water)." | 3.72 | Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. ( Gaballa, M; Goldman, S; Thai, H; Wollmuth, J, 2003) |
| " Recent studies demonstrated an angiotensin II type 1 (AT1)-receptor antagonist reduced myocardial ischemia-reperfusion injury." | 3.71 | Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs. ( Imuro, Y; Iwasaka, T; Izuoka, T; Kitashiro, S; Mimura, J; Miyoshi, H; Saito, D; Takayama, Y; Tokioka, M; Yamamoto, S, 2002) |
| "The purpose of this study was to compare the angiotensin II type 1 receptor antagonist candesartan cilexitil (candesartan) and the angiotensin-converting enzyme inhibitor cilazapril on cardiac function, assessed by Doppler echocardiography and cardiac gene expression associated with cardiac remodeling, in rats with myocardial infarction." | 3.70 | Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. ( Akioka, K; Iwao, H; Kim, S; Omura, T; Takeuchi, K; Teragaki, M; Toda, I; Yamagishi, H; Yoshikawa, J; Yoshiyama, M, 1999) |
| "The calcium antagonist felodipine, the lipid-peroxidation inhibitor H290/51, and the angiotensin II type 1 (AT1)-receptor antagonist candesartan all exert beneficial effects on myocardial ischemia/reperfusion injury." | 3.70 | Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "Candesartan has been reported to reduce cardiovascular events when therapy was started 6 months after PCI with bare-metal stents in patients who survived restenosis." | 2.82 | Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial. ( Hokimoto, S; Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Tsujita, K; Yamamoto, N, 2016) |
| "Candesartan treatment reduced primary end point risk (5." | 2.71 | Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. ( Kondo, J; Kono, T; Kosaka, T; Matsui, H; Morishima, I; Mukawa, H; Murohara, T; Numaguchi, Y; Okumura, K; Sone, T; Tsuboi, H; Uesugi, M; Yoshida, T, 2003) |
| "With candesartan pretreatment, LV fractional shortening and ejection fraction increased (P<0." | 1.33 | Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction. ( Castellano, L; Do, R; Gaballa, MA; Goldman, S; Juneman, E; Phan, H; Thai, H, 2006) |
| "Myocardial infarction was made by ligation of the coronary artery in Wistar rats." | 1.31 | Angiotensin blockade inhibits SIF DNA binding activities via STAT3 after myocardial infarction. ( Akioka, K; Iwao, H; Kim, S; Omura, T; Takeuchi, K; Teragaki, M; Toda, I; Yamagishi, H; Yoshikawa, J; Yoshiyama, M, 2000) |
| "Pretreatment with imidapril (ACE inhibitor) and candesartan cilexitil (AT1 receptor antagonist) significantly prevented the increase in the phosphorylation of JAK1 at 120 min and STAT3 at 30 and 120 min." | 1.31 | Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. ( Beppu, S; Ishikura, F; Kobayashi, H; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2001) |
| "Myocardial infarction was produced by ligation of the coronary artery in Wistar rats." | 1.31 | Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats. ( Akioka, K; Iwao, H; Kim, S; Omura, T; Shimada, K; Takeuchi, K; Teragaki, M; Yamagishi, H; Yoshikawa, J; Yoshiyama, M, 2001) |
| "Myocardial infarction was induced by 30 min coronary artery occlusion and 3 h reperfusion in the rabbit." | 1.30 | Role of the angiotensin II type 1 receptor in preconditioning against infarction. ( Miura, T; Nakano, A; Shimamoto, K; Suzuki, K; Ura, N, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.11) | 18.2507 |
| 2000's | 36 (59.02) | 29.6817 |
| 2010's | 15 (24.59) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Tezcan, H | 1 |
| Tunçez, A | 1 |
| Demir, K | 1 |
| Altunkeser, BB | 1 |
| Aygül, N | 1 |
| Yalcin, MU | 1 |
| Ates, MS | 1 |
| Aydoğan, C | 1 |
| Polat, OC | 1 |
| Toprak, AM | 1 |
| Cunningham, JW | 1 |
| Vaduganathan, M | 1 |
| Claggett, BL | 1 |
| John, JE | 1 |
| Desai, AS | 1 |
| Lewis, EF | 1 |
| Zile, MR | 1 |
| Carson, P | 1 |
| Jhund, PS | 2 |
| Kober, L | 1 |
| Pitt, B | 1 |
| Shah, SJ | 1 |
| Swedberg, K | 6 |
| Anand, IS | 1 |
| Yusuf, S | 5 |
| McMurray, JJV | 1 |
| Pfeffer, MA | 4 |
| Solomon, SD | 3 |
| Lee, SR | 1 |
| Chae, IH | 1 |
| Kim, HL | 1 |
| Kang, DY | 1 |
| Kim, SH | 1 |
| Kim, HS | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Songur, CM | 1 |
| Songur, MO | 1 |
| Kocabeyoglu, SS | 1 |
| Basgut, B | 1 |
| Lymperopoulos, A | 1 |
| Sturchler, E | 1 |
| Bathgate-Siryk, A | 1 |
| Dabul, S | 1 |
| Garcia, D | 1 |
| Walklett, K | 1 |
| Rengo, G | 1 |
| McDonald, P | 1 |
| Koch, WJ | 1 |
| Badar, AA | 1 |
| Perez-Moreno, AC | 1 |
| Hawkins, NM | 1 |
| Brunton, AP | 1 |
| Wong, CM | 1 |
| Granger, CB | 4 |
| Gardner, RS | 1 |
| Petrie, MC | 1 |
| McMurray, JJ | 5 |
| Hornslien, AG | 1 |
| Sandset, EC | 2 |
| Igland, J | 1 |
| Terént, A | 1 |
| Boysen, G | 1 |
| Bath, PM | 2 |
| Murray, GD | 1 |
| Berge, E | 2 |
| Sakamoto, T | 1 |
| Ogawa, H | 2 |
| Nakao, K | 1 |
| Hokimoto, S | 1 |
| Tsujita, K | 1 |
| Koide, S | 1 |
| Yamamoto, N | 1 |
| Shimomura, H | 1 |
| Matsumura, T | 1 |
| Oshima, S | 1 |
| Kikuta, K | 1 |
| Oka, H | 1 |
| Kimura, K | 1 |
| Matsui, K | 2 |
| Lin, X | 1 |
| Wu, M | 1 |
| Liu, B | 1 |
| Wang, J | 1 |
| Guan, G | 1 |
| Ma, A | 1 |
| Zhang, Y | 1 |
| Jusufovic, M | 1 |
| Kohno, T | 1 |
| Anzai, T | 1 |
| Naito, K | 1 |
| Sugano, Y | 1 |
| Maekawa, Y | 1 |
| Takahashi, T | 1 |
| Yoshikawa, T | 1 |
| Ogawa, S | 2 |
| Abrahamsson, P | 1 |
| Dobson, J | 1 |
| Michelson, EL | 2 |
| Pfeffer, M | 1 |
| Pocock, S | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 1 |
| Honda, T | 1 |
| Haze, K | 1 |
| Nagashima, M | 1 |
| Yamaguchi, J | 1 |
| Origasa, H | 1 |
| Urashima, M | 1 |
| Kjeldsen, SE | 1 |
| Stålhammar, J | 1 |
| Hasvold, P | 1 |
| Bodegard, J | 1 |
| Olsson, U | 1 |
| Russell, D | 1 |
| Ocaranza, MP | 1 |
| Lavandero, S | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Pinto, M | 1 |
| Novoa, U | 1 |
| Apablaza, F | 1 |
| Gonzalez, L | 1 |
| Hernandez, C | 1 |
| Varas, M | 1 |
| Lopez, R | 1 |
| Godoy, I | 1 |
| Verdejo, H | 1 |
| Chiong, M | 1 |
| Jugdutt, BI | 4 |
| Jelani, A | 1 |
| Palaniyappan, A | 2 |
| Idikio, H | 3 |
| Uweira, RE | 1 |
| Menon, V | 3 |
| Jugdutt, CE | 1 |
| Numasawa, Y | 1 |
| Kimura, T | 1 |
| Miyoshi, S | 1 |
| Nishiyama, N | 1 |
| Hida, N | 1 |
| Tsuji, H | 1 |
| Tsuruta, H | 1 |
| Segawa, K | 1 |
| Umezawa, A | 1 |
| Jehle, AB | 1 |
| Xu, Y | 1 |
| Dimaria, JM | 1 |
| French, BA | 1 |
| Epstein, FH | 1 |
| Berr, SS | 1 |
| Roy, RJ | 1 |
| Kemp, BA | 1 |
| Carey, RM | 1 |
| Kramer, CM | 1 |
| Uwiera, RR | 2 |
| Jugdutt, C | 1 |
| Miyoshi, H | 1 |
| Takayama, Y | 1 |
| Kitashiro, S | 1 |
| Izuoka, T | 1 |
| Saito, D | 1 |
| Imuro, Y | 1 |
| Mimura, J | 1 |
| Yamamoto, S | 1 |
| Tokioka, M | 1 |
| Iwasaka, T | 1 |
| Shimizu, T | 1 |
| Komuro, I | 3 |
| Hirayama, H | 1 |
| Hiramitsu, S | 1 |
| Shimizu, K | 1 |
| Yoshida, O | 1 |
| Kurosaki, K | 2 |
| Ikeda, U | 2 |
| Murakami, Y | 2 |
| Takahashi, M | 2 |
| Shimada, K | 3 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Thai, H | 2 |
| Wollmuth, J | 1 |
| Goldman, S | 2 |
| Gaballa, M | 1 |
| Kondo, J | 1 |
| Sone, T | 1 |
| Tsuboi, H | 1 |
| Mukawa, H | 1 |
| Morishima, I | 1 |
| Uesugi, M | 1 |
| Kono, T | 1 |
| Kosaka, T | 1 |
| Yoshida, T | 1 |
| Numaguchi, Y | 1 |
| Matsui, H | 1 |
| Murohara, T | 1 |
| Okumura, K | 1 |
| Füessl, HS | 1 |
| Yoshiyama, M | 5 |
| Omura, T | 5 |
| Yoshikawa, J | 5 |
| Verma, S | 1 |
| Strauss, M | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Ostergren, JB | 1 |
| Gerstein, HC | 1 |
| Olofsson, B | 2 |
| Probstfield, J | 1 |
| McMurray, JV | 1 |
| Suzuki, H | 2 |
| Kanno, Y | 2 |
| Nakamura, T | 1 |
| Takenaka, T | 1 |
| Tanonaka, K | 1 |
| Yoshida, H | 1 |
| Koshimizu, M | 1 |
| Oikawa, R | 1 |
| Daicho, T | 1 |
| Takeo, S | 1 |
| Demers, C | 1 |
| McKelvie, RS | 1 |
| Ostergren, J | 1 |
| Johansson, PA | 1 |
| Wang, D | 1 |
| Cheung, BM | 1 |
| Kohara, K | 1 |
| Momomura, S | 1 |
| Tschöpe, C | 1 |
| Schultheiss, HP | 1 |
| Castellano, L | 1 |
| Juneman, E | 1 |
| Phan, H | 1 |
| Do, R | 1 |
| Gaballa, MA | 1 |
| Kudo, Y | 1 |
| Akazawa, H | 1 |
| Kinugawa, S | 1 |
| Nakano, A | 1 |
| Miura, T | 1 |
| Ura, N | 1 |
| Suzuki, K | 1 |
| Shimamoto, K | 1 |
| Harada, K | 1 |
| Hayashi, D | 1 |
| Sugaya, T | 1 |
| Murakami, K | 1 |
| Yazaki, Y | 1 |
| Shimizu, M | 4 |
| Wang, QD | 3 |
| Sjöquist, PO | 3 |
| Rydén, L | 3 |
| Jalowy, A | 1 |
| Schulz, R | 2 |
| Dörge, H | 1 |
| Behrends, M | 2 |
| Heusch, G | 2 |
| Takeuchi, K | 4 |
| Kim, S | 3 |
| Yamagishi, H | 3 |
| Toda, I | 2 |
| Teragaki, M | 3 |
| Akioka, K | 3 |
| Iwao, H | 3 |
| Sharma, A | 1 |
| Singh, M | 1 |
| Weidenbach, R | 1 |
| Gres, P | 1 |
| Post, H | 1 |
| Ishikura, F | 1 |
| Kobayashi, H | 1 |
| Beppu, S | 1 |
| Itoh, H | 1 |
| Mizuno, S | 1 |
| Ohnaka, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation[NCT00139386] | Phase 4 | 1,119 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction[NCT04128891] | Phase 3 | 0 participants (Actual) | Interventional | 2020-02-01 | Withdrawn (stopped due to Funding not approved) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
9 reviews available for candesartan and Myocardial Infarction
| Article | Year |
|---|---|
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineraloc | 2004 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
[Study on cognition and prognosis in the elderly].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2006 |
[CHARM].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2001 |
16 trials available for candesartan and Myocardial Infarction
| Article | Year |
|---|---|
Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients.
Topics: Echocardiography; Humans; Myocardial Infarction; Prospective Studies; Ventricular Remodeling | 2023 |
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Double | 2020 |
Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Brachial Artery; | 2017 |
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; | 2015 |
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; F | 2015 |
Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.
Topics: Aged; Angina, Unstable; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2016 |
Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin II | 2009 |
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2009 |
Inhibition of the renin-angiotensin system: no effect on circulating macrophage colony-stimulating factor levels in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2003 |
Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2003 |
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Coronar | 2003 |
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2005 |
Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2005 |
[Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiotonic Agent | 2006 |
36 other studies available for candesartan and Myocardial Infarction
| Article | Year |
|---|---|
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Effects of the AT1 receptor blocker candesartan on myocardial ischemia/reperfusion in isolated rat hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; In Vitro Techn | 2014 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; H | 2014 |
Candesartan ameliorates acute myocardial infarction in rats through inducible nitric oxide synthase, nuclear factor‑κB, monocyte chemoattractant protein‑1, activator protein‑1 and restoration of heat shock protein 72.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Caspase 3; Cas | 2015 |
Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; | 2008 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2010 |
Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; A | 2010 |
Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; | 2011 |
A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Coronary Occlu | 2012 |
Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Bipheny | 2013 |
Influence of angiotensin II type 1-receptor antagonist CV11974 on infarct size and adjacent regional function after ischemia-reperfusion in dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; | 2002 |
[Drug therapies following heart failure and myocardial infarction(discussion)].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2002 |
Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arteries; Benzimidazoles; Biphenyl Compounds; Blot | 2003 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
[Acute coronary syndrome you can hear the prognosis].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Coronary Arte | 2004 |
AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Hem | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphen | 2004 |
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2004 |
Effects of angiotensin I-converting enzyme inhibitor and angiotensin II type 1 receptor blocker on the right ventricular sarcoglycans and dystrophin after left coronary artery ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2005 |
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Topics: Aged; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; | 2005 |
Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Male; Myocardi | 2006 |
Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2007 |
Role of the angiotensin II type 1 receptor in preconditioning against infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 1997 |
Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias.
Topics: Angiotensin Receptor Antagonists; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; | 1998 |
Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Coronary Circulation; | 1998 |
Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Bradykinin; Bradykini | 1998 |
Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriure | 1999 |
Role of angiotensin in cardioprotective effect of ischemic preconditioning.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Coron | 1999 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzim | 1999 |
The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Ant | 1999 |
Angiotensin blockade inhibits SIF DNA binding activities via STAT3 after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; B | 2000 |
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2000 |
Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2001 |
Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2001 |
[Cardiovascular imaging in-a-month. A 49-year-old man with lip swelling. Angioedema associated with angiotensin II receptor blockade].
Topics: Angioedema; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Humans; Lip; Lip D | 2001 |